These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 30572736)

  • 21. Progress and contrasts of the development of tivozanib for therapy of kidney cancer.
    Gupta S; Fishman M
    Expert Opin Pharmacother; 2011 Dec; 12(18):2915-22. PubMed ID: 22098229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective.
    Choueiri TK
    Curr Clin Pharmacol; 2011 Aug; 6(3):164-8. PubMed ID: 21827394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy.
    Tannir N; Hammers H; Amin A
    Curr Med Res Opin; 2018 May; 34(5):825-831. PubMed ID: 29297707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.
    Agarwala SS; Case S
    Oncologist; 2010; 15(3):236-45. PubMed ID: 20215359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cabozantinib for the treatment of renal cell carcinoma.
    Escudier B; Lougheed JC; Albiges L
    Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Medical treatment of renal cell carcinoma].
    Guy L; Bay JO; Bastide C; Mahammedi H; Bruyere F; Karsenty G
    Prog Urol; 2013 Nov; 23(15):1225-37. PubMed ID: 24183081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding the importance of smart drugs in renal cell carcinoma.
    Patard JJ; Rioux-Leclercq N; Fergelot P
    Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma.
    Li W; Feng C; Di W; Hong S; Chen H; Ejaz M; Yang Y; Xu TR
    Eur J Med Chem; 2020 Aug; 200():112482. PubMed ID: 32492594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.
    Reed JP; Posadas EM; Figlin RA
    Expert Rev Anticancer Ther; 2019 Mar; 19(3):259-271. PubMed ID: 30669895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
    Mulders P
    BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors.
    Desai A; Small EJ
    Future Oncol; 2019 Jul; 15(20):2337-2348. PubMed ID: 31184937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
    Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
    BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tivozanib: a new treatment option for renal cell carcinoma.
    Saes L; Eskens FALM
    Drugs Today (Barc); 2017 Nov; 53(11):609-618. PubMed ID: 29451277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
    Zakharia Y; Zakharia K; Rixe O
    Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
    Alonso-Gordoa T; García-Bermejo ML; Grande E; Garrido P; Carrato A; Molina-Cerrillo J
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted agents for the treatment of advanced renal cell carcinoma.
    Stadler WM
    Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis.
    Iacovelli R; Sternberg CN; Porta C; Verzoni E; de Braud F; Escudier B; Procopio G
    Curr Drug Targets; 2015; 16(2):164-70. PubMed ID: 25410406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.